Endocrine and cardiovascular influences of converting enzyme inhibition with SQ 14225 in hypertensive patients in the supine position and during head-up tilt before and after sodium depletion

A. Morganti, T. G. Pickering, J. A. Lopez-Ovejero, J. H. Laragh

Research output: Contribution to journalArticle

Abstract

In this study we examined the effects of the orally active angiotensin-converting enzyme inhibitor SQ 14225 (Captopril) on blood pressure, heart rate, plasma norepinephrine and epinephrine, PRA, aldosterone, cortisol, and serum potassium in 15 sodium-repleted hypertensive patients in the supine position and during 30 min of head-up tilt; in 3 patients the same investigations were repeated after sodium deprivation. On normal sodium intake, a short term treatment with SQ 14225, at average doses of 480 ± 60 mg/day, reduced mean supine blood pressure by 19 ± 3 mm Hg (P

Original languageEnglish
Pages (from-to)748-754
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume50
Issue number4
Publication statusPublished - 1980

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Endocrine and cardiovascular influences of converting enzyme inhibition with SQ 14225 in hypertensive patients in the supine position and during head-up tilt before and after sodium depletion'. Together they form a unique fingerprint.

  • Cite this